Nublexa 40 MG Tablet contains Neratinib 40mg, an irreversible pan-HER tyrosine kinase inhibitor approved for extended adjuvant treatment of HER2-positive early breast cancer following trastuzumab-based therapy.

How It Works: Neratinib covalently inhibits HER1, HER2, and HER4 tyrosine kinase domains, providing comprehensive and sustained blockade of HER family signaling that drives HER2-amplified cancer cell growth.

Common Uses: Extended adjuvant treatment of HER2-positive early-stage breast cancer after completing trastuzumab (typically 1 year of neratinib for 12 months).

Administration: Take once daily with food. Prophylactic antidiarrheal therapy (loperamide) is strongly recommended during the first 56 days due to high incidence of diarrhea.

Storage: Store below 25°C in a dry location. Keep in original blister packaging out of children's reach.

Disclaimer: This product requires a valid prescription. Consult a licensed oncologist before use. This information is for educational purposes only.